Detecting the
Undetectable
Detecting the
Undetectable
with
EVIIVE
Interception of inter-cell communication to advance precision & personalized medicine
Empowering precision immunotherapy through blood-based diagnostics that decode immune signals and guide treatment with unmatched clarity, speed, and scalability.
Empowering precision immunotherapy through blood-based diagnostics that decode immune signals and guide treatment with unmatched clarity, speed, and scalability.
Empowering precision immunotherapy through blood-based diagnostics that decode immune signals and guide treatment with unmatched clarity, speed, and scalability.
At EVIIVE, we are on a mission to transform the treatment selection of cancer through our innovative extracellular vesicle biomarker discovery platforms, IMPASS & IMPACT.
Redefining immunotherapy strategy through EV (extracellular vesicles) profiling
Redefining immunotherapy strategy through EV (extracellular vesicles) profiling
Redefining immunotherapy strategy through EV (extracellular vesicles) profiling
Single EV-driven multi-omics approach built upon decade of R&D
Single EV-driven multi-omics approach built upon decade of R&D
Single EV-driven multi-omics approach built upon decade of R&D
Stratifying patients by decoding personalized cell-type specific EV signals
Stratifying patients by decoding personalized cell-type specific EV signals
Stratifying patients by decoding personalized cell-type specific EV signals
Driving next-generation companion diagnostics backed by scientific and clinical experts
Driving next-generation companion diagnostics backed by scientific and clinical experts
Driving next-generation companion diagnostics backed by scientific and clinical experts
“Precision and scalability don’t have to compete. We’re building a diagnostic platform that does both—starting with early-stage treatment selection in immuno-oncology.”
“Precision and scalability don’t have to compete. We’re building a diagnostic platform that does both—starting with early-stage treatment selection in immuno-oncology.”
“Precision and scalability don’t have to compete. We’re building a diagnostic platform that does both—starting with early-stage treatment selection in immuno-oncology.”
Current landscape
Current landscape
Current landscape
Most patients receive first-line IO treatment without knowing if it will work—wasting time, money, and precious response windows.
70%
70%
70%
Around 70% of patients do not respond to first-line IO treatment (> 6 million worldwide per year)
Around 70% of patients do not respond to first-line IO treatment (> 6 million worldwide per year)
Around 70% of patients do not respond to first-line IO treatment (> 6 million worldwide per year)
90%
90%
90%
More than 90% non-responders irreversibly progress (e.g. metastasis, resistance, <6 months survival)
More than 90% non-responders irreversibly progress (e.g. metastasis, resistance, <6 months survival)
More than 90% non-responders irreversibly progress (e.g. metastasis, resistance, <6 months survival)
60%
60%
60%
More than 60% of Phase III IO trials fail due to poor stratification
More than 60% of Phase III IO trials fail due to poor stratification
More than 60% of Phase III IO trials fail due to poor stratification
60%
60%
60%
Around 60% accuracy in predicting IO response using existing biomarkers & technologies
Around 60% accuracy in predicting IO response using existing biomarkers & technologies
Around 60% accuracy in predicting IO response using existing biomarkers & technologies
Source: Cell, Journal for immunotherapy of cancer, Journal of Pathology and National Library of Medicine
Biomarker Opportunity
Biomarker Opportunity
Biomarker Opportunity
Liquid biopsies EV – the untapped communication system between host immune system and tumor environment.
Unique Biology
EVs are tissue-specific, sensitive, and comprehensive—carrying parental cell and tissue markers, preserving conserved cell–cell signaling pathways, and crossing tissue boundaries to provide a holistic biological snapshot.
Unique Biology
EVs are tissue-specific, sensitive, and comprehensive—carrying parental cell and tissue markers, preserving conserved cell–cell signaling pathways, and crossing tissue boundaries to provide a holistic biological snapshot.
Unique Biology
EVs are tissue-specific, sensitive, and comprehensive—carrying parental cell and tissue markers, preserving conserved cell–cell signaling pathways, and crossing tissue boundaries to provide a holistic biological snapshot.
High Volume, High Fidelity
Secreted exclusively by living and actively growing tissues, these particles are naturally abundant (10 million/µL), enabling real-time, high-resolution insights into physiological states.
High Volume, High Fidelity
Secreted exclusively by living and actively growing tissues, these particles are naturally abundant (10 million/µL), enabling real-time, high-resolution insights into physiological states.
High Volume, High Fidelity
Secreted exclusively by living and actively growing tissues, these particles are naturally abundant (10 million/µL), enabling real-time, high-resolution insights into physiological states.
Exceptional Stability
Engineered by nature to withstand harsh environments, the particles remain stable for 2 days at room temperature, 2 weeks at 4°C, and for years when frozen—offering unmatched consistency for clinical and research use.
Exceptional Stability
Engineered by nature to withstand harsh environments, the particles remain stable for 2 days at room temperature, 2 weeks at 4°C, and for years when frozen—offering unmatched consistency for clinical and research use.
Exceptional Stability
Engineered by nature to withstand harsh environments, the particles remain stable for 2 days at room temperature, 2 weeks at 4°C, and for years when frozen—offering unmatched consistency for clinical and research use.
Why EVIIVE
Why EVIIVE
Why EVIIVE
“Most current biomarkers rely on indirect signals. We’re working with something more immediate—extracellular vesicles—as a way to observe biology closer to how it actually behaves.”
Our Vision
Our Vision
Our Vision
Eviive’s EV biomarker technology empowers precise IO treatment at the right time for every patient with an improved prediction power and the potential to make a clinically meaningful difference for patients with cancer.
